Drugs / elzovantinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03993873 | Sep 2019 → Jan 2024 overdue | metastatic neoplasm, neoplasm | Turning Point Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | elzovantinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03993873 ↗ |
| Known as | TPX-0022 | “Oral elzovantinib (TPX-0022) capsules” NCT03993873 ↗ |
| Modality | Small molecule | — CHEMBL5095061 ↗ |
| Route | Oral | “Oral elzovantinib (TPX-0022) capsules” NCT03993873 ↗ |